1
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Head and Neck Neoplasms
1
Interventions
Cisplatin
3193
Cyclophosphamide
3187
Carboplatin
2968
Radiotherapy
2784
Paclitaxel
2716
Gemcitabine
2569
pembrolizumab
2378
Bevacizumab
2206
Docetaxel
2196
Fluorouracil
1848
Capecitabine
1828
Oxaliplatin
1738
Dexamethasone
1604
Nivolumab
1580
Doxorubicin
1501
Rituximab
1487
Magnetic Resonance Spectroscopy
1382
Etoposide
1345
Irinotecan
1245
Leucovorin
1222
Drug Therapy
1202
Cytarabine
1130
Pemetrexed
1074
fludarabine
1056
Specimen Handling
1009
Vincristine
964
Cetuximab
943
Prednisone
940
Trastuzumab
940
Lenalidomide
937
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
combretastatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn